Arbutus Biopharma Corporation

ABUS · NASDAQ
Analyze with AI
9/30/2025
6/30/2025
3/31/2025
12/31/2024
Operating Activities
Net Income-$7,742$2,523-$24,526-$12,532
Dep. & Amort.$11$11$330$333
Deferred Tax$0$0$0$0
Stock-Based Comp.$1,263$864$3,564$1,632
Change in WC$1,150-$18,240$5,269-$229
Other Non-Cash-$499-$907$1,972$481
Operating Cash Flow-$5,817-$15,749-$13,391-$10,315
Investing Activities
PP&E Inv.$0$9$0-$86
Net Acquisitions$0$0$0$0
Inv. Purchases-$51,300-$28,498-$34,716-$43,191
Inv. Sales/Matur.$41,281$44,100$46,065$56,688
Other Inv. Act.$0$0$0$0
Investing Cash Flow-$10,019$15,611$11,349$13,411
Financing Activities
Debt Repay.$0$0$0$0
Stock Issued$0$0$0-$1
Stock Repurch.$0$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.$844$453$2,784$1,422
Financing Cash Flow$844$453$2,784$1,421
Forex Effect-$12$21$4-$33
Net Chg. in Cash-$15,004$336$746$4,484
Supplemental Information
Beg. Cash$37,412$37,076$36,330$31,846
End Cash$22,408$37,412$37,076$36,330
Free Cash Flow-$5,817-$15,749-$13,391-$10,401